Market revenue in 2023 | USD 306.6 million |
Market revenue in 2030 | USD 1,490.1 million |
Growth rate | 25.3% (CAGR from 2023 to 2030) |
Largest segment | Consumables |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Consumables, Services |
Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Pacific Biosciences of California Inc, Birks Group Inc Class A, Qiagen NV, Agilent Technologies Inc, Macrogenics Inc, Azenta Inc, PerkinElmer, ProPhase Labs Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to short-read sequencing market will help companies and investors design strategic landscapes.
Consumables was the largest segment with a revenue share of 61.81% in 2023. Horizon Databook has segmented the China short-read sequencing market based on instruments, consumables, services covering the revenue growth of each sub-segment from 2018 to 2030.
China is expected to play a leading role in advancement of cutting-edge precision medicine globally. For this, the country is focused on advancements in the field of precision medicine, population genomics, clinical diagnostics, and personal wellness. The move is already reported to be attracting private investments.
Chinese players such as Beijing Genomics Institute (BGI), WuXi PharmaTech, Novogene, and Cloud Health have purchased state-of-the-art sequencing technology from Illumina to support China’s precision-medicine initiative. Moreover, local players have also collaborated with hospitals to enhance the use of precision medicine in the country.
Moreover, local presence of prominent sequencing players such as BGI accounts for a significant share of China in the Asia-Pacific short read sequencing market. BGI has also integrated NGS platforms and applications such as pre-natal screening, oncology, idiopathic and infectious disease investigation and research in China, and has installed over 120 HiSeq 2000 genome sequencers by Illumina.
Horizon Databook provides a detailed overview of country-level data and insights on the China short-read sequencing market , including forecasts for subscribers. This country databook contains high-level insights into China short-read sequencing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account